Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Lupus ; 27(5): 788-793, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29251169

ABSTRACT

Objective (a) to assess the prevalence of functional gastrointestinal disorders (FGIDs) in female Mexican systemic lupus erythematosus (SLE) patients using the Rome III criteria and (b) to examine the effect of disease duration on FGID prevalence. Methods Female SLE outpatients aged ≥18 years with no organic gastrointestinal disorder were included. Participants were invited to upper gastrointestinal endoscopy screening and a faecal immunochemical test. FGID symptoms were evaluated using the Rome III questionnaire. Results Eighty-six SLE patients with median age of 45 (interquartile range 34-54) years were included. At least one FGID was found in 76.7% (66/88) of patients with SLE. The most prevalent domains of FGID diagnosed were functional oesophageal, gastroduodenal disorders and bowel disorders, of which functional dyspepsia (72.7%), functional heartburn (68.1%) and bloating (63.8%) were the most frequent. Fifty-nine per cent of patients had overlapping FGIDs. The most prevalent overlap was the combination of functional dyspepsia and functional heartburn. Patients with longer disease duration had a higher prevalence of FGID than those with shorter disease duration. Conclusions There was a high prevalence of FGIDs in Mexican SLE women with low disease activity. Overlapping FGIDs were frequent. Longer disease duration may be associated with FGIDs in SLE patients.


Subject(s)
Gastrointestinal Diseases/epidemiology , Lupus Erythematosus, Systemic/epidemiology , Adolescent , Adult , Cross-Sectional Studies , Dyspepsia/diagnosis , Dyspepsia/epidemiology , Endoscopy, Gastrointestinal , Feces/chemistry , Female , Gastrointestinal Diseases/diagnosis , Heartburn/diagnosis , Heartburn/epidemiology , Humans , Immunohistochemistry , Lupus Erythematosus, Systemic/diagnosis , Mexico/epidemiology , Middle Aged , Prevalence , Surveys and Questionnaires , Time Factors , Young Adult
2.
Lupus ; 24(11): 1227-32, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26085596

ABSTRACT

The objective of this cross-sectional study was to determine relationships between socioeconomic status and organ damage in Mexican systemic lupus erythematosus (SLE) patients. Demographic and clinical variables were assessed. Socioeconomic status was evaluated using the Graffar method and monthly household income. Lupus activity and organ damage were measured using the SLE disease activity scale, validated for the Mexican population (Mex-SLEDAI), and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) scale. The 143 Mexican female SLE patients included (mean age 40.1 ± 8.9 years, mean disease duration 8.9 ± 6.3 years) had a mean monthly household income of $ 407.2 ± 326.5. According to the Graffar index, 18.9%, 52.5%, and 28.7% had high/medium-high, medium, and medium-low/low socioeconomic status, respectively. Organ damage was observed in 61 patients (42.7%). Patients with organ damage had lower monthly household incomes ($241.4 ± 152.4 vs. $354.8 ± 288.3) and were more frequently unemployed (57.3% vs. 35.3%; p = 0.01) than those without. Low monthly income was not associated with lupus activity or self-reported health status. In the adjusted multivariate analysis, low monthly income ( < $300) was associated with organ damage. In conclusion, low income may be associated with organ damage in Mexican SLE patients.


Subject(s)
Lupus Erythematosus, Discoid/economics , Lupus Erythematosus, Discoid/pathology , Lupus Erythematosus, Systemic/economics , Lupus Erythematosus, Systemic/pathology , Multiple Organ Failure/economics , Multiple Organ Failure/pathology , Adult , Cross-Sectional Studies , Female , Health Status , Humans , Mexico , Middle Aged , Multivariate Analysis , Severity of Illness Index , Social Class , Women's Health
3.
Autoimmun Rev ; 14(7): 594-600, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25712147

ABSTRACT

P-glycoprotein (Pgp) is a transmembrane protein of 170 kD encoded by the multidrug resistance 1 (MDR-1) gene, localized on chromosome 7. More than 50 polymorphisms of the MDR-1 gene have been described; a subset of these has been shown to play a pathophysiological role in the development of inflammatory bowel disease, femoral head osteonecrosis induced by steroids, lung cancer and renal epithelial tumors. Polymorphisms that have a protective effect on the development of conditions such as Parkinson disease have also been identified. P-glycoprotein belongs to the adenosine triphosphate binding cassette transporter superfamily and its structure comprises a chain of approximately 1280 aminoacid residues with an N-C terminal structure, arranged as 2 homologous halves, each of which has 6 transmembrane segments, with a total of 12 segments with 2 cytoplasmic nucleotide binding domains. Many cytokines like interleukin 2 and tumor necrosis factor alpha increase Pgp expression and activity. Pgp functions as an efflux pump for a variety of toxins in order to protect particular organs and tissues as the central nervous system. Pgp transports a variety of substrates including glucocorticoids while other drugs such as tacrolimus and cyclosporine A act as modulators of this protein. The most widely used method to measure Pgp activity is flow cytometry using naturally fluorescent substrates such as anthracyclines or rhodamine 123. The study of drug resistance and its association to Pgp began with the study of resistance to chemotherapy in the treatment of cancer and antiretroviral therapy for human immunodeficiency virus; however, the role of Pgp in the treatment of systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis has been a focus of study lately and has emerged as an important mechanism by which treatment failure occurs. The present review analyzes the role of Pgp in these autoimmune diseases.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/immunology , Autoimmune Diseases/immunology , Rheumatic Diseases/immunology , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Animals , Humans , Polymorphism, Genetic , Substrate Specificity
4.
Lupus ; 24(6): 606-12, 2015 May.
Article in English | MEDLINE | ID: mdl-25411259

ABSTRACT

Our objective was to evaluate whether vitamin D deficiency is associated with cervical human papilloma virus (HPV) infection in women with SLE. This is a cross-sectional study of 67 women with SLE. A structured questionnaire was administered to ascertain the possible risk factors associated with cervical HPV infection. A gynaecological evaluation and cervical cytology screening were made. HPV detection and genotyping was made by PCR and linear array assay. Serum 25 hydroxyvitamin D levels were quantified by chemiluminescence immunoassay. Mean age and disease duration were 44.8 ± 10.6 and 42.5 ± 11.8 years, respectively. Demographic characteristics were similar in patients with and without deficiency (<20 ng/ml and ≥20 ng/ml). There were 28.4% of women with cervical HPV infection and 68.4% had high-risk HPV infections. Patients with 25 hydroxyvitamin D levels <20 ng/ml had a higher prevalence of cervical HPV infection than those with levels ≥20 ng/ml (30.7% vs. 25.8%; p = 0.72). We found no significant difference when high-risk HPV infection was evaluated (36.8% vs. 31.5%; p = 0.73). In conclusion, women with SLE have a high prevalence of vitamin D deficiency and cervical HPV infection. However, we found no association between vitamin D deficiency and cervical HPV.


Subject(s)
Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/virology , Papillomavirus Infections/blood , Uterine Cervical Diseases/blood , Uterine Cervical Diseases/virology , Vitamin D/analogs & derivatives , Adult , Cross-Sectional Studies , Female , Genotype , Humans , Immunoassay/methods , Longitudinal Studies , Middle Aged , Polymerase Chain Reaction/methods , Prevalence , Risk Factors , Uterine Cervical Neoplasms/blood , Uterine Cervical Neoplasms/virology , Vaginal Smears/methods , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/virology , Uterine Cervical Dysplasia/blood , Uterine Cervical Dysplasia/virology
SELECTION OF CITATIONS
SEARCH DETAIL